EUCTR2011-003574-84-BE进行中（未招募）1 期
A Randomized, Placebo-controlled, Double-blind,Multicenter Phase II Trial of Intravenous GC33 at 1600 mgQ2W in Previously Treated Patients with UnresectableAdvanced or Metastatic Hepatocellular Carcinoma (HCC).
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 171
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female =18 years old
- •2. Life expectancy of at least 12 weeks
- •3. ECOG Performance Status of 0 or 1
- •4. Histologically confirmed unresectable advanced or metastatic hepatocellular carcinoma (without fibrolamellar subtype) patients who are not candidate for or progressed on loco-regional therapy
- •5. Prior treatment with at least 1 systemic agent, (such as Sorafenib or other experimental agents), with documented progressive disease after systemic agent(s), or documented adverse event(s) associated with prior systemic agent(s) that resulted in discontinuance of that(those) agent(s)
- •6. Not a candidate for curative treatments (e.g. resection, transplantation)
- •7. Child-Pugh A ( score of 5-6)
- •8. Adequate hematologic function: Platelet count = 50x 109/L, Absolute Neutrophil Count = 1,500/µL, Hemoglobin = 8.0 g /dL
- •9. Adequate hepatic function: ALT (SGPT), AST (SGOT) = 5 x ULN, Bilirubin = 2 mg/ dL
- •10. Adequate renal function: Serum Creatinine = 2 x ULN or calculated Creatinine Clearance = 60 ml/min using Cockcroft and Gault formula
- •11. Ability to provide, for central review, a tumor tissue sample containing at least 5 % tumor cells to determine the level of GPC-3 expression by IHC. Determination of GPC-3 expression level is required prior to study entry.
- •12. Patients must have recovered from effects of any major surgery or significant traumatic injury at least 14 days before the first dose of study treatment
- •13. Measurable disease (by RECIST 1.1) prior to the administration of study treatment
- •14. Negative serum pregnancy test
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 85
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 86
排除标准
- •1. Child-Pugh B or C
- •2. Known HCC with fibro-lamellar histology
- •3. Known brain or leptomeningeal metastases
- •4. Patients with a previous malignancy within the past 5 years are excluded(patients who had curatively treated basal cell carcinoma of the skin,early gastrointestinal cancer by endoscopic resection, and/or insitu carcinoma of the cervix and other malignancies which were considered cured and deemed by the PI to have no impact on the PFS and OS are allowed after discussion with the study medical monitor)
- •5. Active infectious diseases requiring treatment except for hepatitis B and C
- •6. NCI CTCAE version 4.0 grade 3 hemorrhage within 4 weeks of starting the study treatment
- •7. History of organ allograft including liver transplant
- •8. Anticipated or ongoing administration of anti-cancer therapies other than those administered in this study
- •9. Patient who have had any anticancer treatment within 2 weeks prior to entering the study
- •10. Patients who have not fully recovered from toxicities associated with previous HCC loco-regional or systemic therapies
- •11. Patients receiving Interferon therapy
- •12. Patients with baseline QTc > 470 ms, or patients with baseline resting bradycardia <45 beats per minutes.
- •13. Patients who received anticoagulation or thrombolytic agents for therapeutic purposes (except for low-dose administration for catheter clearance or for prophylactic purposes) within 2 weeks prior to Day 1
研究者
相似试验
进行中（未招募）
1 期
Study of intravenous GC33 treatment in patients with liver cancer that cannot be resected or has metastatized and that has not responded to currently available treatment(s).EUCTR2011-003574-84-DEF. Hoffmann-La Roche Ltd.156
进行中（未招募）
1 期
Study of intravenous GC33 treatment in patients with liver cancer that cannot be resected or has metastatized and that has not responded to currently available treatment(s).Second-line treatment for adult patient with unresectableadvanced or metastatic hepatocellular cancer.MedDRA version: 14.0Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-003574-84-ESF. Hoffmann-La Roche Ltd.156
进行中（未招募）
1 期
Study of intravenous GC33 treatment in patients with liver cancer that cannot be resected or has metastatized and that has not responded to currently available treatment(s).Second-line treatment for adult patient with unresectable advanced or metastatic hepatocellular cancer.MedDRA version: 14.1 Level: LLT Classification code 10019828 Term: Hepatocellular carcinoma non-resectable System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-003574-84-GBF. Hoffmann-La Roche Ltd.185
进行中（未招募）
1 期
A Study of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS)Primary Sjogren's SyndromeMedDRA version: 21.0Level: LLTClassification code 10040766Term: Sjogren's diseaseSystem Organ Class: 100000004859EUCTR2021-000665-32-ITJANSSEN CILAG INTERNATIONAL NV150
尚未招募
2 期
A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS)Primary Sjögren's Syndromchronicprogressive autoimmune disease10003816NL-OMON52271Janssen-Cilag4